About Birken
Birken is a company based in Niefern-oschelbronn (Germany) founded in 2000 was acquired by Amryt Pharma in March 2016. Birken operates in a competitive market with competitors including Alnylam, Ultragenyx, Gemini Therapeutics, BioMarin Pharmaceutical and Homology Medicines, among others.
- Headquarter Niefern-oschelbronn, Germany
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
-
Acquired by
Amryt Pharma
(Mar 31, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Birken
Detailed funding history for Birken
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Birken
Birken has secured backing from 1 investor. Prominent investors backing the company include Amryt Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Therapeutics for rare dermatological and orphan diseases are developed.
|
Locked | Locked | Locked |
Investor details for Birken
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Birken
Investment portfolio details for Birken
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Birken
Detailed financials for Birken
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Birken Comparisons
Peer comparison for Birken
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Birken
Birken operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alnylam, Ultragenyx, Gemini Therapeutics, BioMarin Pharmaceutical and Homology Medicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of precision therapeutics for dry AMD and rare genetic diseases
|
|
| Locked | Locked | Locked |
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for rare genetic diseases
|
|
| Locked | Locked | Locked |
Small molecule therapeutics are developed for rare diseases treatment.
|
Detailed competitors of Birken
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Birken
Complete news archive for Birken
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Birken
Birken was founded in 2000.
Birken is headquartered in Niefern-oschelbronn, Germany. It is registered at Niefern-oschelbronn, Baden-wurttemberg, Germany.
Joseph Wiley is the current CEO of Birken.
Birken was founded in 2000 as a German clinical-stage biopharmaceutical company. Focus was placed on developing botanical extracts, particularly Episalvan from birch bark, for epidermolysis bullosa treatment. Orphan Drug designations were obtained in the US and Europe. Anti-microbial and anti-inflammatory properties are shown by Episalvan, supporting skin repair processes. Operations centered in Germany until acquisition by Amryt Pharma in 2016.
Birken's top competitors include Alnylam, BioMarin Pharmaceutical and Pharvaris.
Birken has 1 investor. Key investors include Amryt Pharma.